JPS60158181A - ジヒドロピリダジノン誘導体 - Google Patents

ジヒドロピリダジノン誘導体

Info

Publication number
JPS60158181A
JPS60158181A JP60003912A JP391285A JPS60158181A JP S60158181 A JPS60158181 A JP S60158181A JP 60003912 A JP60003912 A JP 60003912A JP 391285 A JP391285 A JP 391285A JP S60158181 A JPS60158181 A JP S60158181A
Authority
JP
Japan
Prior art keywords
compound
methyl
formula
item
pyridazinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60003912A
Other languages
English (en)
Japanese (ja)
Inventor
ロバート・アントニイ・スレイター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of JPS60158181A publication Critical patent/JPS60158181A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
JP60003912A 1984-01-13 1985-01-11 ジヒドロピリダジノン誘導体 Pending JPS60158181A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8400863 1984-01-13
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (1)

Publication Number Publication Date
JPS60158181A true JPS60158181A (ja) 1985-08-19

Family

ID=10554924

Family Applications (3)

Application Number Title Priority Date Filing Date
JP60003912A Pending JPS60158181A (ja) 1984-01-13 1985-01-11 ジヒドロピリダジノン誘導体
JP63113411A Pending JPS63313776A (ja) 1984-01-13 1988-05-09 ジヒドロピリダジノン誘導体
JP63113410A Pending JPS63313775A (ja) 1984-01-13 1988-05-09 ジヒドロピリダジノン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP63113411A Pending JPS63313776A (ja) 1984-01-13 1988-05-09 ジヒドロピリダジノン誘導体
JP63113410A Pending JPS63313775A (ja) 1984-01-13 1988-05-09 ジヒドロピリダジノン誘導体

Country Status (31)

Country Link
US (1) US4654342A (enExample)
EP (1) EP0150937B1 (enExample)
JP (3) JPS60158181A (enExample)
KR (1) KR920006781B1 (enExample)
CN (1) CN85101722A (enExample)
AT (1) ATE37179T1 (enExample)
AU (1) AU572252B2 (enExample)
CA (2) CA1251209A (enExample)
CS (1) CS248731B2 (enExample)
DD (1) DD231350A5 (enExample)
DE (1) DE3564941D1 (enExample)
DK (1) DK162519C (enExample)
ES (3) ES8607949A1 (enExample)
FI (1) FI850140A7 (enExample)
GB (1) GB8400863D0 (enExample)
GR (1) GR850068B (enExample)
HU (1) HU193591B (enExample)
IE (1) IE57969B1 (enExample)
IL (1) IL74031A (enExample)
JO (1) JO1351B1 (enExample)
MY (1) MY100124A (enExample)
NO (1) NO850129L (enExample)
NZ (1) NZ210816A (enExample)
PH (1) PH22136A (enExample)
PL (1) PL147123B1 (enExample)
PT (1) PT79819B (enExample)
RO (1) RO92607A (enExample)
SU (1) SU1396963A3 (enExample)
WO (1) WO1985003076A1 (enExample)
ZA (1) ZA85251B (enExample)
ZW (1) ZW385A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
WO2002068381A2 (en) * 2001-02-27 2002-09-06 Mitokor Aryl-n-cyanoguanidines and methods related thereto
JP5116940B2 (ja) * 2001-11-05 2013-01-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ヒドラゾノ−マロニトリル類
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
CN102784394A (zh) * 2005-11-14 2012-11-21 贝林格尔·英格海姆维特梅迪卡有限公司 磷酸二酯酶iii型抑制剂或者钙增敏剂用于治疗无症状(潜隐性)心力衰竭的用途
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL2370070T3 (pl) 2008-11-25 2014-02-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
HRP20251029T1 (hr) 2013-07-19 2025-10-24 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
MX375926B (es) 2013-08-09 2025-03-07 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
EP3106150B1 (en) 2013-12-04 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Improved pharmaceutical compositions of pimobendan
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
EP0059688B1 (de) * 1981-03-04 1985-05-15 Ciba-Geigy Ag Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones

Also Published As

Publication number Publication date
ZW385A1 (en) 1985-08-07
JPS63313775A (ja) 1988-12-21
US4654342A (en) 1987-03-31
JO1351B1 (en) 1986-11-30
PL147123B1 (en) 1989-04-29
ES8607949A1 (es) 1986-06-01
DD231350A5 (de) 1985-12-24
CN85101722A (zh) 1987-01-31
DK162519C (da) 1992-03-30
CA1260471C (enExample) 1989-09-26
PT79819B (en) 1987-01-07
KR920006781B1 (ko) 1992-08-17
AU572252B2 (en) 1988-05-05
CA1251209A (en) 1989-03-14
DK162519B (da) 1991-11-11
PT79819A (en) 1985-02-01
AU3761185A (en) 1985-07-18
ZA85251B (en) 1986-08-27
WO1985003076A1 (en) 1985-07-18
JPS63313776A (ja) 1988-12-21
DK9185A (da) 1985-07-14
HUT37128A (en) 1985-11-28
ES8706645A1 (es) 1987-07-01
NZ210816A (en) 1987-06-30
GB8400863D0 (en) 1984-02-15
GR850068B (enExample) 1985-05-03
ES549629A0 (es) 1987-03-01
FI850140L (fi) 1985-07-14
PH22136A (en) 1988-06-01
PL251516A1 (en) 1985-12-17
RO92607A (ro) 1987-11-30
ES539446A0 (es) 1986-06-01
EP0150937B1 (en) 1988-09-14
HU193591B (en) 1987-11-30
ES554965A0 (es) 1987-07-01
IE57969B1 (en) 1993-06-02
NO850129L (no) 1985-07-15
EP0150937A3 (en) 1985-08-21
EP0150937A2 (en) 1985-08-07
SU1396963A3 (ru) 1988-05-15
IE850069L (en) 1985-07-13
ES8703846A1 (es) 1987-03-01
IL74031A (en) 1988-07-31
CA1260471A (en) 1989-09-26
IL74031A0 (en) 1985-04-30
DK9185D0 (da) 1985-01-08
FI850140A7 (fi) 1985-07-14
CS248731B2 (en) 1987-02-12
FI850140A0 (fi) 1985-01-11
MY100124A (en) 1989-12-18
DE3564941D1 (en) 1988-10-20
KR850005417A (ko) 1985-08-26
ATE37179T1 (de) 1988-09-15

Similar Documents

Publication Publication Date Title
JPS60158181A (ja) ジヒドロピリダジノン誘導体
TWI406865B (zh) 傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）之氮呯（ａｚｅｐｉｎｅ）抑制劑
DE69609602T2 (de) Pyrazolderivate und verfahren zu deren herstellung
EP0201188A2 (en) 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds
US4663326A (en) Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
DE102006029447A1 (de) Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
DE3724164A1 (de) Neue 1,4-benzodiazepine, ihre herstellung und verwendung
PL189572B1 (pl) Związek wybrany spośród pirydyloftalazynodionów, kompozycja farmaceutyczna, zastosowanie związku i sposób wytwarzania związku
EP0208518A2 (en) 6-Phenyl-pyridazinyl compounds
JP2022518556A (ja) ヤーヌスキナーゼ（ｊａｋ）ファミリー阻害剤及びその調製と使用
CA1252788A (en) Pyridazinone derivatives
JP6542236B2 (ja) 有機化合物
DD266355A5 (de) Verfahren zur herstellung von neuen 1,4-benzodiozepinen
EP0304534A1 (de) Dihydropyridazinon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1989140B (zh) 用于抑制nad(p)h氧化酶和血小板活化的含有与稠合环部分连接的n-杂芳基部分的化合物
US4766123A (en) Methylamidine compounds
US4766122A (en) Cyanoamidine compounds and derivatives thereof
JPS61212583A (ja) ２‐アミノピリミジノン誘導体
JPH06500108A (ja) 治療薬
US20120214846A1 (en) Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
US4962110A (en) Pyridazinone derivatives
JP4537710B2 (ja) ファルネシルトランスフェラーゼ阻害剤としての炭素連結トリアゾールで置換されている１，８−アネル化キノリン誘導体
JPS61212582A (ja) ジヒドロピリダジノン誘導体
JPS6212764A (ja) ジヒドロピリダジノン誘導体
JPS5818363A (ja) 複素環式置換アミノピラゾリン類およびその薬としての用途